Yourway Mitigates Uncertainty of Brexit
Yourway, courier and clinical packager offering integrated clinical trial supply chain solutions, announced its establishment of a new location within the European Union providing storage and distribution services, including secondary packaging capabilities, located 40 minutes from the Vienna, Austria airport in Bratislava, Slovakia. This move was designed to ensure uninterrupted support for clients’ trials in both the UK and mainland Europe if the United Kingdom leaves the EU on the current deadline of October 31, especially in the event of a no-deal Brexit.
“The new location in Europe mitigates the uncertainty of Brexit for our clients, in order to service their clinical trial needs. It includes Qualified Person (QP) release services within Europe prior to release for use in a Clinical Trial, as required by Clinical Trial Directive 2001/20/EC and Annex 13 to the European GMP Guide.” said Yourway President and Founder, Gulam Jaffer.
“Through our Project Managers and QP release personnel, and use of our global network of GMP depots, we can assure safe and timely delivery of clinical trial materials to patients,” he added.
Yourway provides a full range of temperature-controlled solutions designed to protect clinical trial shipments from the time an order is received through to delivery on time for patient dosing protocols. It is also offering an integrated supply chain with no differences in quality to traditional multi-provider models in this market.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
